| Catalog No. | Size | Price (USD) |
| 16014-H08H-1 | 1 mg | $3,730.91 |
| 16014-H08H-50 | 50 µg | $342.14 |
| 16014-H08H-100 | 100 µg | $573.19 |
General Information
| Formulation | Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Shipping | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
| Stability & Storage | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution | To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA. |
| Purity | ≥ 95 % as determined by SDS-PAGE ≥ 95 % as determined by SEC-HPLC. |
| Activity | 1.Loaded Monoclonal anti-human LILRB1 Antibody, human IgG4 on ProA Biosensor, can bind Recombinant Human ILT2/LILRB1 Protein, His Tag (Cat. No. 16014-H08H) with an affinity constant of 9.53 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 2.Immobilized anti-LILRB1, Human IgG4 at 2 μg/mL (100 μL/well) can bind Recombinant Human LILRB1 / CD85 / ILT2 / ILR1 Protein (ECD, His Tag) (Cat: 16014-H08H), the EC 50 is 2.5-7.5 ng/mL. |
| Protein Construction | A DNA sequence encoding the human LILRB1 (ADJ55949.1) (Met1-His458) was expressed with a C-terminal polyhistidine tag. |
| Accession# | ADJ55949.1 |
| Expressed Host | HEK293 Cells |
| Species | Human |
| Predicted N Terminal | Gly 24 |
| Molecule Mass | The recombinant human LILRB1 comprises 446 amino acids and has a predicted molecular mass of 48.6 kDa. The apparent molecular mass of the protein is approximately 61-68 kDa in SDS-PAGE under reducing conditions due to glycosylation. |
Synonyms: CD85 Protein, Human; CD85J Protein, Human; ILT-2 Protein, Human; ILT2 Protein, Human; LIR-1 Protein, Human; LIR1 Protein, Human; MIR-7 Protein, Human; MIR7 Protein, Human; PIR-B Protein, Human; PIRB Protein, Human
Image / Experimental Information
| Image 1 Alt Text | Human LILRB1/CD85j/ILT2 Protein 10901 |
| Image 1 URL | Source image |
| Image 2 Alt Text | Human LILRB1 Protein 36370 |
| Image 2 URL | Source image |
| Image 3 Alt Text | Human ILT2/LILRB1 Protein 39318 |
| Image 3 URL | Source image |
| Image 4 Alt Text | Human ILT2/LILRB1 Protein 39605 |
| Image 4 URL | Source image |
Background Information
| Full Name | leukocyte immunoglobulin like receptor B1 |
| Description | LILRB1 (Leukocyte Immunoglobulin Like Receptor B1) is a Protein Coding gene. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). LILRB1 is encoded within the leukocyte receptor complex on 19q13.4, previously implicated to be a susceptibility region to systemic lupus erythematosus (SLE). LILRB1 binds to a wide range of Major Histocompatibility Complex Class I molecules (MHCIs) and transduces negative signals that can, for example, prevent the killing of MHCI-expressing cells. LILRB1 transcription is correlated with surface protein expression on NK cells. Diseases associated with LILRB1 include Alzheimer's Disease 12 and Severe Pre-Eclampsia. |
| Research Areas |
|
title: Multispecific single domain antibodies chimeric antigen receptor and T-cell engager, nucleic acid, expressing cell thereof, pharmaceutical composition for treating cancer, and method for inhibiting proliferation of tumor cell
authors: Der-Yang Cho; Shao-Chih Chiu; ...; Chung-Chun Wu
date: 2025-12-30
cited_by_count: 0
techniques: Activity Assay; Binding Assay; Blocking Assay; Competitive ELISA; Control; Recombinant
bioz_score: 93
title: Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
authors: Der-Yang Cho; Shao-Chih Chiu; ...; Yeh Chen
date: 2024-06-18
cited_by_count: 0
techniques: Activity Assay; Blocking Assay; Concentration Assay; Enzyme-linked Immunosorbent Assay; Incubation
bioz_score: 93
title: BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
authors: Shi-Wei Huang; Chih-Ming Pan; ...; Der-Yang Cho
journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
date: 2023-06-15
pmid: 37078788
doi: 10.1002/advs.202206856
cited_by_count: 32
techniques: Competitive ELISA; Enzyme-linked Immunosorbent Assay; Gradient Centrifugation; Incubation; Isolation; Recombinant; Saline
bioz_score: 93
title: BiTE‐Secreting CAR‐ γδ T as a Dual Targeting Strategy for the Treatment of Solid Tumors
authors: Shi‐Wei Huang; Chih‐Ming Pan; ...; Der‐Yang Cho
journal: Advanced Science
date: 2023-04-20
pmid: 37078788
pmcid: 10265101
cited_by_count: 32
techniques: Activity Assay; Binding Assay; Blocking Assay; Clone Assay; Competitive ELISA; Construct; Cytotoxicity Assay; Derivative Assay; Enzyme-linked Immunosorbent Assay; Expressing; Flow Cytometry; Functional Assay; Incubation; Modification; Recombinant
bioz_score: 93
title: BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
authors: Ilana Mandel; Dana Haves Ziv; ...; Tehila Ben Moshe
journal: Journal for Immunotherapy of Cancer
date: 2022-01-01
pmid: 36096532
pmcid: 9472153
cited_by_count: 28
techniques: Binding Assay; Chromatin Immunoprecipitation
bioz_score: 93
